US equities |
SPCX $168.76 ▲+6.17% NVDA $237.54 ▲+1.53% MU $1,065.03 ▼-0.92% TSLA $380.49 ▲+2.67% MSFT $524.64 ▲+1.37% SNDK $1,714.31 ▼-0.33% INTC $116.81 ▼-2.11% META $744.16 ▲+2.21%
FinancialContent

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

5.380 -0.160 (-2.89%)
Delayed Quote Updated: 1:29 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at APASL 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
How Is The Market Feeling About Aligos Therapeutics? ↗
 
Via Benzinga
News headline image
Monday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? ↗
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir... 
Via Benzinga
Topics Economy Stocks
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For March 10, 2025 ↗
 
Via Benzinga
News headline image
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces $105 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Investor Conferences in December
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Investor Conferences in October
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Reverse Stock Split
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Board with Two New Independent Directors
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >